Profile data is unavailable for this security.
About the company
Vigil Neuroscience, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in its efforts to develop precision-based therapies to improve the lives of patients and their families. Its lead clinical candidate, VGL101 (iluzanebart), is a fully human monoclonal antibody TREM2 agonist that is being studied in a Phase 2 proof-of-concept trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia. The Company is also developing VG-3927, its orally available small molecule TREM2 agonist program to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer’s disease in genetically defined subpopulations.
- Revenue in USD (TTM)0.00
- Net income in USD-82.78m
- Incorporated2020
- Employees65.00
- LocationVigil Neuroscience Inc100 Forge Road, Suite 700WATERTOWN 02472United StatesUSA
- Phone+1 (857) 254-4445
- Websitehttps://www.vigilneuro.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Immunic Inc | 0.00 | -97.92m | 114.40m | 77.00 | -- | 1.37 | -- | -- | -1.84 | -1.84 | 0.00 | 0.9278 | 0.00 | -- | -- | 0.00 | -91.94 | -72.09 | -110.91 | -80.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.25 | -- | -10.97 | -- |
| FibroGen Inc | 167.49m | -240.46m | 115.39m | 486.00 | -- | -- | -- | 0.6889 | -2.45 | -2.45 | 1.70 | -2.29 | 0.3704 | 1.18 | 5.05 | 344,635.80 | -53.71 | -30.62 | -124.24 | -42.31 | 75.46 | 93.52 | -145.02 | -119.08 | 1.27 | -36.51 | -- | -- | 4.99 | -7.05 | 3.21 | -- | -20.67 | -- |
| Sangamo Therapeutics Inc | 18.76m | -328.05m | 116.49m | 405.00 | -- | 2.02 | -- | 6.21 | -1.86 | -1.86 | 0.1057 | 0.2784 | 0.0659 | -- | 4.86 | 46,311.11 | -115.20 | -26.09 | -139.17 | -31.04 | -- | -- | -1,749.06 | -136.53 | -- | -- | 0.00 | -- | 58.34 | 15.85 | -34.09 | -- | -13.25 | -- |
| aTyr Pharma Inc | 588.00k | -53.93m | 116.63m | 56.00 | -- | 1.37 | -- | 198.35 | -0.9029 | -0.9029 | 0.0099 | 1.24 | 0.0047 | -- | 0.2868 | 10,500.00 | -43.13 | -45.45 | -48.85 | -52.74 | -- | -- | -9,172.11 | -784.19 | -- | -- | 0.021 | -- | -96.60 | -- | -11.14 | -- | 47.98 | -- |
| Vor Biopharma Inc | 0.00 | -117.86m | 116.65m | 168.00 | -- | 0.7702 | -- | -- | -1.75 | -1.75 | 0.00 | 2.22 | 0.00 | -- | -- | 0.00 | -47.38 | -45.79 | -50.28 | -48.98 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.98 | -- | -- | -- |
| Nuvectis Pharma Inc | 0.00 | -22.26m | 117.57m | 13.00 | -- | 9.14 | -- | -- | -1.42 | -1.42 | 0.00 | 0.7005 | 0.00 | -- | -- | 0.00 | -112.45 | -- | -168.51 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -16.64 | -- | -- | -- |
| Vistagen Therapeutics Inc | 1.04m | -32.07m | 118.10m | 37.00 | -- | 0.958 | -- | 113.31 | -3.56 | -3.56 | 0.0775 | 4.56 | 0.013 | -- | -- | 31,584.85 | -39.89 | -77.80 | -42.10 | -85.00 | -- | -- | -3,076.62 | -8,640.25 | -- | -- | 0.00006 | -- | -120.50 | -- | -21.64 | -- | 165.73 | -- |
| DiaMedica Therapeutics Inc | 0.00 | -19.38m | 118.45m | 18.00 | -- | 2.32 | -- | -- | -0.6168 | -0.6168 | 0.00 | 1.35 | 0.00 | -- | -- | 0.00 | -43.77 | -45.38 | -46.37 | -48.24 | -- | -- | -- | -- | -- | -- | 0.00008 | -- | -- | -- | -41.72 | -- | -13.65 | -- |
| Amylyx Pharmaceuticals Inc | 398.00m | -71.10m | 119.35m | 384.00 | -- | 0.3677 | -- | 0.2999 | -1.07 | -1.07 | 5.74 | 4.77 | 0.9644 | 6.74 | 21.00 | 1,036,461.00 | -17.23 | -- | -20.84 | -- | 88.93 | -- | -17.86 | -- | 4.48 | -- | 0.00 | -- | 1,612.94 | -- | 124.84 | -- | -- | -- |
| Vigil Neuroscience Inc | 0.00 | -82.78m | 119.52m | 65.00 | -- | 1.15 | -- | -- | -2.12 | -2.12 | 0.00 | 2.76 | 0.00 | -- | -- | 0.00 | -52.16 | -- | -54.92 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.98 | -- | -- | -- |
| Coya Therapeutics Inc | 6.00m | -7.99m | 119.88m | 8.00 | -- | 3.32 | -- | 19.97 | -0.8219 | -0.8219 | 0.5906 | 2.47 | 0.2417 | -- | -- | 750,276.30 | -32.17 | -- | -39.17 | -- | -- | -- | -133.08 | -- | -- | -- | 0.00 | -- | -- | -- | 34.77 | -- | -- | -- |
| Rezolute Inc | 0.00 | -56.83m | 119.98m | 51.00 | -- | 1.29 | -- | -- | -1.11 | -1.11 | 0.00 | 2.31 | 0.00 | -- | -- | 0.00 | -45.04 | -58.48 | -47.75 | -63.38 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -26.13 | -- | 92.29 | -- |
| Adicet Bio Inc | 0.00 | -142.66m | 120.79m | 143.00 | -- | 0.3738 | -- | -- | -3.32 | -3.32 | 0.00 | 3.93 | 0.00 | -- | -- | 0.00 | -53.03 | -37.03 | -57.18 | -40.28 | -- | -- | -- | -748.46 | -- | -- | 0.00 | -- | -100.00 | -- | -104.41 | -- | 65.27 | -- |
| Vaxart Inc | 7.38m | -82.47m | 124.67m | 109.00 | -- | 1.87 | -- | 16.90 | -0.5844 | -0.5844 | 0.0519 | 0.3767 | 0.0601 | -- | 4.87 | 67,697.25 | -67.13 | -49.60 | -77.06 | -54.86 | -- | -- | -1,117.56 | -1,398.00 | -- | -- | 0.10 | -- | 6,796.26 | 12.15 | 23.47 | -- | 21.49 | -- |
| Citius Pharmaceuticals Inc | 0.00 | -39.33m | 125.32m | 22.00 | -- | 1.30 | -- | -- | -0.255 | -0.255 | 0.00 | 0.533 | 0.00 | -- | -- | 0.00 | -36.52 | -30.26 | -38.61 | -32.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -0.1589 | -- | -- | -- |
Data as of May 10 2024. Currency figures normalised to Vigil Neuroscience Inc's reporting currency: US Dollar USD
28.77%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Citadel Advisors LLCas of 31 Dec 2023 | 2.16m | 5.86% |
| BVF Partners LPas of 31 Dec 2023 | 1.81m | 4.92% |
| Invus Public Equities Advisors LLCas of 29 Mar 2024 | 1.81m | 4.91% |
| Deep Track Capital LPas of 31 Dec 2023 | 1.59m | 4.32% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 830.83k | 2.25% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 786.16k | 2.13% |
| Sphera Funds Management Ltd.as of 31 Dec 2023 | 535.12k | 1.45% |
| Rock Springs Capital Management LPas of 31 Dec 2023 | 471.96k | 1.28% |
| Geode Capital Management LLCas of 31 Dec 2023 | 315.54k | 0.86% |
| ArrowMark Colorado Holdings LLCas of 31 Dec 2023 | 289.46k | 0.79% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
